Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report

BACKGROUND: A variety of immune-modulating drugs are becoming increasingly used for various cancers. Despite increasing indications and improved efficacy, they are often associated with a wide variety of immune mediated adverse events including colitis that may be refractory to conventional therapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Nassri, Ammar B, Muenyi, Valery, AlKhasawneh, Ahmad, Ribeiro, Bruno De Souza, Scolapio, James S, Malespin, Miguel, de Melo Jr, Silvio W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347649/
https://www.ncbi.nlm.nih.gov/pubmed/30697447
http://dx.doi.org/10.4292/wjgpt.v10.i1.29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347649/
https://www.ncbi.nlm.nih.gov/pubmed/30697447
http://dx.doi.org/10.4292/wjgpt.v10.i1.29

Ejemplares similares